{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.19","value":"1902"},{"groupId":"OG001","spread":"31.02","value":"1699"},{"groupId":"OG002","spread":"28.15","value":"1790"},{"groupId":"OG003","spread":"25.09","value":"1526"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.76","value":"156.1"},{"groupId":"OG001","spread":"34.21","value":"134.0"},{"groupId":"OG002","spread":"30.69","value":"144.6"},{"groupId":"OG003","spread":"19.56","value":"118.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 1 Day 1: N-desmethyl selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.81","value":"3095"},{"groupId":"OG001","spread":"49.23","value":"2114"},{"groupId":"OG002","spread":"52.23","value":"2575"},{"groupId":"OG003","spread":"32.08","value":"1952"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: Selumetinib"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.37","value":"192.9"},{"groupId":"OG001","spread":"33.82","value":"135.9"},{"groupId":"OG002","spread":"37.97","value":"161.9"},{"groupId":"OG003","spread":"14.64","value":"143.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cycle 2 Day 1: N-desmethyl selumetinib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"32"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"To further evaluate the PK of the granule formulation.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"},{"description":"Japan Cohort (\\>=1 to \\<7 years)","id":"OG003","title":"Japan Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4, 6, 8, 10-12 and 18-24 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1). Pre-dose, 1, 2, 3, 4, 6, 8, and 10-12 hours post-dose on Cycle 2 Day 1 (each cycle is 28 days)","title":"Selumetinib and N-desmethyl Selumetinib AUC0-12 Derived After Single and Multiple Dose Administration","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}